Cargando…
Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
INTRODUCTION: The magnitude of response to immune checkpoint inhibitor (ICI) therapy may be sex-dependent, as females have lower response rates and decreased survival after ICI monotherapy. The mechanisms underlying this sex dimorphism in ICI response are unknown, and may be related to sex-driven di...
Autores principales: | Scott, Susan C., Shao, Xiaoshan M., Niknafs, Noushin, Balan, Archana, Pereira, Gavin, Marrone, Kristen A., Lam, Vincent K., Murray, Joseph C., Feliciano, Josephine L., Levy, Benjamin P., Ettinger, David S., Hann, Christine L., Brahmer, Julie R., Forde, Patrick M., Karchin, Rachel, Naidoo, Jarushka, Anagnostou, Valsamo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382103/ https://www.ncbi.nlm.nih.gov/pubmed/35992816 http://dx.doi.org/10.3389/fonc.2022.945798 |
Ejemplares similares
-
Persistent mutation burden drives sustained anti-tumor immune responses
por: Niknafs, Noushin, et al.
Publicado: (2023) -
Tracing the genetic fingerprints of tumour evolution: The pursuit of identifying mutations with differential weights within the overall tumour mutation burden and their role in therapeutic responses with immune checkpoint blockade
por: Niknafs, Noushin, et al.
Publicado: (2023) -
CLRM-11 ALK TYROSINE KINASE INHIBITOR THERAPY AND BRAIN METASTASES IN NON-SMALL CELL LUNG CANCER: IMPACT ON TUMOR SIZE AND DISTRIBUTION
por: Kamson, David Olayinka, et al.
Publicado: (2023) -
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
por: Hsu, Melinda L, et al.
Publicado: (2022) -
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)